Does Cosentyx Affect Vaccine Immunity?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, suppresses parts of the immune system but does not broadly impair vaccine responses like some other biologics. Clinical studies show patients on Cosentyx produce antibodies after certain vaccinations, though responses may be weaker for live vaccines.[1]
Which Vaccines Are Safe on Cosentyx?
Non-live vaccines (inactivated or recombinant) are recommended and effective:
- COVID-19 vaccines (e.g., Pfizer, Moderna): Antibody responses are comparable to healthy adults, with good T-cell immunity.[2]
- Influenza vaccine: Seroprotection rates similar to placebo groups in trials.[1]
- Pneumococcal and tetanus vaccines: Protective antibody levels achieved in most patients.[3]
Avoid live vaccines (e.g., MMR, varicella, oral polio, yellow fever) due to infection risk from immunosuppression. Data is limited, but guidelines advise against them.[1][4]
How Strong Is the Immunity Built?
Response rates are generally 70-90% for non-live vaccines, versus 90-100% in non-immunosuppressed people. For example:
- Shingrix (shingles vaccine): Strong antibody and T-cell responses observed.[5]
- HPV vaccine: Adequate seroconversion in studies.[3]
Factors like age, disease severity, and concurrent steroids can reduce efficacy. Booster doses may help.[1]
Timing Vaccines with Cosentyx Doses
Vaccinate before starting Cosentyx if possible. If already on it:
- Give non-live vaccines anytime; peak response expected 2-4 weeks post-vaccination.
- Hold Cosentyx 1-2 weeks before/after high-priority vaccines if clinically feasible, per some expert guidance.[4]
No need to stop Cosentyx for routine non-live shots.
Patient Experiences and Real-World Data
Reports from psoriasis forums and registries note successful vaccinations without breakthrough infections, but some describe milder side effects or perceived weaker protection. Long-term studies confirm sustained immunity against tetanus/diphtheria for years post-vaccination.[3]
Consult your doctor for personalized advice, especially if high-risk.
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] PubMed: Secukinumab and COVID-19 vaccine response
[3] Clinical Trials: Vaccine responses in IL-17 inhibitors
[4] AAD Guidelines on Biologics and Vaccines
[5] Journal of Rheumatology: Shingrix in autoimmune disease